Rationally Designed Small Molecules That Target Both the DNA and RNA Causing Myotonic Dystrophy Type 1

Single-agent, single-target therapeutic approaches are often limited by a complex disease pathobiology. We report rationally designed, multi-target agents for myotonic dystrophy type 1 (DM1). DM1 originates in an abnormal expansion of CTG repeats (CTGexp) in the DMPK gene. The resultant expanded CUG...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Chemical Society 2015-11, Vol.137 (44), p.14180-14189
Hauptverfasser: Nguyen, Lien, Luu, Long M, Peng, Shaohong, Serrano, Julio F, Chan, H. Y. Edwin, Zimmerman, Steven C
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 14189
container_issue 44
container_start_page 14180
container_title Journal of the American Chemical Society
container_volume 137
creator Nguyen, Lien
Luu, Long M
Peng, Shaohong
Serrano, Julio F
Chan, H. Y. Edwin
Zimmerman, Steven C
description Single-agent, single-target therapeutic approaches are often limited by a complex disease pathobiology. We report rationally designed, multi-target agents for myotonic dystrophy type 1 (DM1). DM1 originates in an abnormal expansion of CTG repeats (CTGexp) in the DMPK gene. The resultant expanded CUG transcript (CUGexp) identified as a toxic agent sequesters important proteins, such as muscleblind-like proteins (MBNL), undergoes repeat-associated non-ATG (RAN) translation, and potentially causes microRNA dysregulation. We report rationally designed small molecules that target the DM1 pathobiology in vitro in three distinct ways by acting simultaneously as transcription inhibitors, by inhibiting aberrant protein binding to the toxic RNA, and by acting as RNase mimics to degrade the toxic RNA. In vitro, the agents are shown to (1) bind CTGexp and inhibit formation of the CUGexp transcript, (2) bind CUGexp and inhibit sequestration of MBNL1, and (3) cleave CUGexp in an RNase-like manner. The most potent compounds are capable of reducing the levels of CUGexp in DM1 model cells, and one reverses two separate CUGexp-induced phenotypes in a DM1 Drosophila model.
doi_str_mv 10.1021/jacs.5b09266
format Article
fullrecord <record><control><sourceid>acs_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1021_jacs_5b09266</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>a461378881</sourcerecordid><originalsourceid>FETCH-LOGICAL-a324t-3d0822f27e31344c4cccbda5b3571e7b2abf837cf719debdadea718ee52dd3c13</originalsourceid><addsrcrecordid>eNptkDtPwzAUhS0EoqWwMSOPDKT4lTgdS8tLakEqYY4c-6ZJlcZR7Az596RqYWI6OrrfPcOH0C0lU0oYfdwp7aZhRmYsis7QmIaMBCFl0TkaE0JYIOOIj9CVc7uhChbTSzRikZBcRGKM8o3ypa1VVfV4Ca7c1mDw137oeG0r0F0FDieF8jhR7RY8frK-wL4AvPyYY1UbvBlyoTpX1lu87q23danxsne-tU3R46RvANNrdJGrysHNKSfo--U5WbwFq8_X98V8FSjOhA-4ITFjOZPAKRdCC611ZlSY8VBSkBlTWR5zqXNJZwaGiwElaQwQMmO4pnyCHo67urXOtZCnTVvuVdunlKQHXelBV3rSNeB3R7zpsj2YP_jXzwDcH4HD18527WDK_b_1A5e-dAo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Rationally Designed Small Molecules That Target Both the DNA and RNA Causing Myotonic Dystrophy Type 1</title><source>MEDLINE</source><source>American Chemical Society Journals</source><creator>Nguyen, Lien ; Luu, Long M ; Peng, Shaohong ; Serrano, Julio F ; Chan, H. Y. Edwin ; Zimmerman, Steven C</creator><creatorcontrib>Nguyen, Lien ; Luu, Long M ; Peng, Shaohong ; Serrano, Julio F ; Chan, H. Y. Edwin ; Zimmerman, Steven C</creatorcontrib><description>Single-agent, single-target therapeutic approaches are often limited by a complex disease pathobiology. We report rationally designed, multi-target agents for myotonic dystrophy type 1 (DM1). DM1 originates in an abnormal expansion of CTG repeats (CTGexp) in the DMPK gene. The resultant expanded CUG transcript (CUGexp) identified as a toxic agent sequesters important proteins, such as muscleblind-like proteins (MBNL), undergoes repeat-associated non-ATG (RAN) translation, and potentially causes microRNA dysregulation. We report rationally designed small molecules that target the DM1 pathobiology in vitro in three distinct ways by acting simultaneously as transcription inhibitors, by inhibiting aberrant protein binding to the toxic RNA, and by acting as RNase mimics to degrade the toxic RNA. In vitro, the agents are shown to (1) bind CTGexp and inhibit formation of the CUGexp transcript, (2) bind CUGexp and inhibit sequestration of MBNL1, and (3) cleave CUGexp in an RNase-like manner. The most potent compounds are capable of reducing the levels of CUGexp in DM1 model cells, and one reverses two separate CUGexp-induced phenotypes in a DM1 Drosophila model.</description><identifier>ISSN: 0002-7863</identifier><identifier>EISSN: 1520-5126</identifier><identifier>DOI: 10.1021/jacs.5b09266</identifier><identifier>PMID: 26473464</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Animals ; Disease Models, Animal ; DNA - genetics ; DNA - metabolism ; Drosophila ; Drug Design ; HeLa Cells ; Humans ; Myotonic Dystrophy - drug therapy ; Myotonic Dystrophy - genetics ; Myotonic Dystrophy - pathology ; RNA - biosynthesis ; RNA - genetics ; RNA - metabolism ; Small Molecule Libraries - chemical synthesis ; Small Molecule Libraries - chemistry ; Small Molecule Libraries - pharmacology ; Trinucleotide Repeat Expansion - drug effects ; Trinucleotide Repeat Expansion - genetics</subject><ispartof>Journal of the American Chemical Society, 2015-11, Vol.137 (44), p.14180-14189</ispartof><rights>Copyright © 2015 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a324t-3d0822f27e31344c4cccbda5b3571e7b2abf837cf719debdadea718ee52dd3c13</citedby><cites>FETCH-LOGICAL-a324t-3d0822f27e31344c4cccbda5b3571e7b2abf837cf719debdadea718ee52dd3c13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jacs.5b09266$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jacs.5b09266$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,780,784,2765,27076,27924,27925,56738,56788</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26473464$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nguyen, Lien</creatorcontrib><creatorcontrib>Luu, Long M</creatorcontrib><creatorcontrib>Peng, Shaohong</creatorcontrib><creatorcontrib>Serrano, Julio F</creatorcontrib><creatorcontrib>Chan, H. Y. Edwin</creatorcontrib><creatorcontrib>Zimmerman, Steven C</creatorcontrib><title>Rationally Designed Small Molecules That Target Both the DNA and RNA Causing Myotonic Dystrophy Type 1</title><title>Journal of the American Chemical Society</title><addtitle>J. Am. Chem. Soc</addtitle><description>Single-agent, single-target therapeutic approaches are often limited by a complex disease pathobiology. We report rationally designed, multi-target agents for myotonic dystrophy type 1 (DM1). DM1 originates in an abnormal expansion of CTG repeats (CTGexp) in the DMPK gene. The resultant expanded CUG transcript (CUGexp) identified as a toxic agent sequesters important proteins, such as muscleblind-like proteins (MBNL), undergoes repeat-associated non-ATG (RAN) translation, and potentially causes microRNA dysregulation. We report rationally designed small molecules that target the DM1 pathobiology in vitro in three distinct ways by acting simultaneously as transcription inhibitors, by inhibiting aberrant protein binding to the toxic RNA, and by acting as RNase mimics to degrade the toxic RNA. In vitro, the agents are shown to (1) bind CTGexp and inhibit formation of the CUGexp transcript, (2) bind CUGexp and inhibit sequestration of MBNL1, and (3) cleave CUGexp in an RNase-like manner. The most potent compounds are capable of reducing the levels of CUGexp in DM1 model cells, and one reverses two separate CUGexp-induced phenotypes in a DM1 Drosophila model.</description><subject>Animals</subject><subject>Disease Models, Animal</subject><subject>DNA - genetics</subject><subject>DNA - metabolism</subject><subject>Drosophila</subject><subject>Drug Design</subject><subject>HeLa Cells</subject><subject>Humans</subject><subject>Myotonic Dystrophy - drug therapy</subject><subject>Myotonic Dystrophy - genetics</subject><subject>Myotonic Dystrophy - pathology</subject><subject>RNA - biosynthesis</subject><subject>RNA - genetics</subject><subject>RNA - metabolism</subject><subject>Small Molecule Libraries - chemical synthesis</subject><subject>Small Molecule Libraries - chemistry</subject><subject>Small Molecule Libraries - pharmacology</subject><subject>Trinucleotide Repeat Expansion - drug effects</subject><subject>Trinucleotide Repeat Expansion - genetics</subject><issn>0002-7863</issn><issn>1520-5126</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkDtPwzAUhS0EoqWwMSOPDKT4lTgdS8tLakEqYY4c-6ZJlcZR7Az596RqYWI6OrrfPcOH0C0lU0oYfdwp7aZhRmYsis7QmIaMBCFl0TkaE0JYIOOIj9CVc7uhChbTSzRikZBcRGKM8o3ypa1VVfV4Ca7c1mDw137oeG0r0F0FDieF8jhR7RY8frK-wL4AvPyYY1UbvBlyoTpX1lu87q23danxsne-tU3R46RvANNrdJGrysHNKSfo--U5WbwFq8_X98V8FSjOhA-4ITFjOZPAKRdCC611ZlSY8VBSkBlTWR5zqXNJZwaGiwElaQwQMmO4pnyCHo67urXOtZCnTVvuVdunlKQHXelBV3rSNeB3R7zpsj2YP_jXzwDcH4HD18527WDK_b_1A5e-dAo</recordid><startdate>20151111</startdate><enddate>20151111</enddate><creator>Nguyen, Lien</creator><creator>Luu, Long M</creator><creator>Peng, Shaohong</creator><creator>Serrano, Julio F</creator><creator>Chan, H. Y. Edwin</creator><creator>Zimmerman, Steven C</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20151111</creationdate><title>Rationally Designed Small Molecules That Target Both the DNA and RNA Causing Myotonic Dystrophy Type 1</title><author>Nguyen, Lien ; Luu, Long M ; Peng, Shaohong ; Serrano, Julio F ; Chan, H. Y. Edwin ; Zimmerman, Steven C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a324t-3d0822f27e31344c4cccbda5b3571e7b2abf837cf719debdadea718ee52dd3c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Disease Models, Animal</topic><topic>DNA - genetics</topic><topic>DNA - metabolism</topic><topic>Drosophila</topic><topic>Drug Design</topic><topic>HeLa Cells</topic><topic>Humans</topic><topic>Myotonic Dystrophy - drug therapy</topic><topic>Myotonic Dystrophy - genetics</topic><topic>Myotonic Dystrophy - pathology</topic><topic>RNA - biosynthesis</topic><topic>RNA - genetics</topic><topic>RNA - metabolism</topic><topic>Small Molecule Libraries - chemical synthesis</topic><topic>Small Molecule Libraries - chemistry</topic><topic>Small Molecule Libraries - pharmacology</topic><topic>Trinucleotide Repeat Expansion - drug effects</topic><topic>Trinucleotide Repeat Expansion - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nguyen, Lien</creatorcontrib><creatorcontrib>Luu, Long M</creatorcontrib><creatorcontrib>Peng, Shaohong</creatorcontrib><creatorcontrib>Serrano, Julio F</creatorcontrib><creatorcontrib>Chan, H. Y. Edwin</creatorcontrib><creatorcontrib>Zimmerman, Steven C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of the American Chemical Society</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nguyen, Lien</au><au>Luu, Long M</au><au>Peng, Shaohong</au><au>Serrano, Julio F</au><au>Chan, H. Y. Edwin</au><au>Zimmerman, Steven C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rationally Designed Small Molecules That Target Both the DNA and RNA Causing Myotonic Dystrophy Type 1</atitle><jtitle>Journal of the American Chemical Society</jtitle><addtitle>J. Am. Chem. Soc</addtitle><date>2015-11-11</date><risdate>2015</risdate><volume>137</volume><issue>44</issue><spage>14180</spage><epage>14189</epage><pages>14180-14189</pages><issn>0002-7863</issn><eissn>1520-5126</eissn><abstract>Single-agent, single-target therapeutic approaches are often limited by a complex disease pathobiology. We report rationally designed, multi-target agents for myotonic dystrophy type 1 (DM1). DM1 originates in an abnormal expansion of CTG repeats (CTGexp) in the DMPK gene. The resultant expanded CUG transcript (CUGexp) identified as a toxic agent sequesters important proteins, such as muscleblind-like proteins (MBNL), undergoes repeat-associated non-ATG (RAN) translation, and potentially causes microRNA dysregulation. We report rationally designed small molecules that target the DM1 pathobiology in vitro in three distinct ways by acting simultaneously as transcription inhibitors, by inhibiting aberrant protein binding to the toxic RNA, and by acting as RNase mimics to degrade the toxic RNA. In vitro, the agents are shown to (1) bind CTGexp and inhibit formation of the CUGexp transcript, (2) bind CUGexp and inhibit sequestration of MBNL1, and (3) cleave CUGexp in an RNase-like manner. The most potent compounds are capable of reducing the levels of CUGexp in DM1 model cells, and one reverses two separate CUGexp-induced phenotypes in a DM1 Drosophila model.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>26473464</pmid><doi>10.1021/jacs.5b09266</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-7863
ispartof Journal of the American Chemical Society, 2015-11, Vol.137 (44), p.14180-14189
issn 0002-7863
1520-5126
language eng
recordid cdi_crossref_primary_10_1021_jacs_5b09266
source MEDLINE; American Chemical Society Journals
subjects Animals
Disease Models, Animal
DNA - genetics
DNA - metabolism
Drosophila
Drug Design
HeLa Cells
Humans
Myotonic Dystrophy - drug therapy
Myotonic Dystrophy - genetics
Myotonic Dystrophy - pathology
RNA - biosynthesis
RNA - genetics
RNA - metabolism
Small Molecule Libraries - chemical synthesis
Small Molecule Libraries - chemistry
Small Molecule Libraries - pharmacology
Trinucleotide Repeat Expansion - drug effects
Trinucleotide Repeat Expansion - genetics
title Rationally Designed Small Molecules That Target Both the DNA and RNA Causing Myotonic Dystrophy Type 1
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A57%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-acs_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rationally%20Designed%20Small%20Molecules%20That%20Target%20Both%20the%20DNA%20and%20RNA%20Causing%20Myotonic%20Dystrophy%20Type%201&rft.jtitle=Journal%20of%20the%20American%20Chemical%20Society&rft.au=Nguyen,%20Lien&rft.date=2015-11-11&rft.volume=137&rft.issue=44&rft.spage=14180&rft.epage=14189&rft.pages=14180-14189&rft.issn=0002-7863&rft.eissn=1520-5126&rft_id=info:doi/10.1021/jacs.5b09266&rft_dat=%3Cacs_cross%3Ea461378881%3C/acs_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/26473464&rfr_iscdi=true